Anika Therapeutics, Inc. (ANIK)
NASDAQ: ANIK · Real-Time Price · USD
17.39
-0.26 (-1.47%)
Feb 21, 2025, 4:00 PM EST - Market closed
Anika Therapeutics Revenue
Anika Therapeutics had revenue of $38.75M in the quarter ending September 30, 2024, a decrease of -6.54%. This brings the company's revenue in the last twelve months to $164.17M, up 0.52% year-over-year. In the year 2023, Anika Therapeutics had annual revenue of $166.66M with 6.67% growth.
Revenue (ttm)
$164.17M
Revenue Growth
+0.52%
P/S Ratio
1.56
Revenue / Employee
$459,854
Employees
357
Market Cap
254.69M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 166.66M | 10.43M | 6.67% |
Dec 31, 2022 | 156.24M | 8.44M | 5.71% |
Dec 31, 2021 | 147.79M | 17.34M | 13.29% |
Dec 31, 2020 | 130.46M | 15.85M | 13.83% |
Dec 31, 2019 | 114.61M | 9.06M | 8.58% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ANIK News
- 2 months ago - Anika To Participate in 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Anika To Participate in December 2024 Investor Conferences - GlobeNewsWire
- 3 months ago - Anika Therapeutics, Inc. (ANIK) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics - PRNewsWire
- 4 months ago - Anika Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 4 months ago - Anika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus Medical - GlobeNewsWire
- 4 months ago - Anika Announces Third Quarter 2024 Results Conference Call Date - GlobeNewsWire
- 5 months ago - Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire